Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd has received a $2 million grant from the U.S. Department of Defense to expedite the development of its RECCE 327 Gel for treating burn wound infections and preventing sepsis in military settings. This funding will support the evaluation of RECCE 327 Gel as an alternative to traditional antimicrobial dressings. The grant, along with a successful A$8 million institutional placement and an open share purchase plan, highlights Recce’s growing influence in the medical field and its commitment to improving health outcomes.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
